RET fusion
Gene: RET · Type: fusion
Indications: Non-small cell lung cancer, Thyroid cancer
Linked CIViC Profile: RET FUSION
Evidence Level Distribution
Level A: 2Level B: 8Level C: 5Level D: 8
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Predisposing | Supports | Predisposition | Medullary Thyroid Carcinoma | 4 | |
| C | Predictive | Supports | Sensitivity/Response | Medullary Thyroid Carcinoma | Selpercatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Medullary Thyroid Carcinoma | Cabozantinib | 4 |
| A | Predictive | Supports | Sensitivity/Response | Medullary Thyroid Carcinoma | Selpercatinib | 4 |
| D | Oncogenic | Supports | Oncogenicity | Cancer | 4 | |
| A | Predictive | Supports | Sensitivity/Response | Medullary Thyroid Carcinoma | Selpercatinib | 4 |
| B | Prognostic | Supports | Poor Outcome | Medullary Thyroid Carcinoma | 3 | |
| D | Predictive | Supports | Resistance | Medullary Thyroid Carcinoma | Motesanib | 3 |
| D | Predictive | Supports | Resistance | Medullary Thyroid Carcinoma | Motesanib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Medullary Thyroid Carcinoma | JAK2 Inhibitor AZD1480 | 3 |
| B | Predictive | Supports | Sensitivity/Response | Medullary Thyroid Carcinoma | Sorafenib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Papillary Adenocarcinoma | Sunitinib | 3 |
| B | Prognostic | Supports | Poor Outcome | Lung Adenocarcinoma | 3 | |
| C | Predictive | Supports | Sensitivity/Response | Medullary Thyroid Carcinoma | Selpercatinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Medullary Thyroid Carcinoma | Selpercatinib | 3 |
| C | Predictive | Supports | Resistance | Medullary Thyroid Carcinoma | Selpercatinib | 3 |
| D | Oncogenic | Supports | Oncogenicity | Cancer | 3 | |
| D | Oncogenic | Supports | Oncogenicity | Cancer | 3 | |
| D | Oncogenic | Supports | Oncogenicity | Cancer | 3 | |
| B | Oncogenic | Supports | Oncogenicity | Medullary Thyroid Carcinoma | 3 |